S100B content and SOD activity in amniotic fluid of pregnancies with Down syndrome

Objectives: We measured S100B levels and superoxide dismutase (SOD) activity retrospectively in amniotic fluid samples from pregnancies with normal and Down syndrome (DS) fetuses.Design and methods: Samples from 26 normal and 71 Down syndrome fetuses were studied. S100B protein levels were determined using LIA-mat Sangtec kit, and SOD activity was measured with the RANSOD kit.Results: We observed significantly higher levels of S100B in the Down group (median of 1.24 μg/l) than in the control group (median 0.69 μg/l). S100B concentration in DS samples increased from the 13th to the 18th week of gestation and was positively correlated with gestational age. The amniotic fluid SOD activity in the DS group (16.60 U/mg/prot) was significantly higher than in the normal one (10.78 U/mg/prot).Conclusions: This study indicates that S100B and SOD in amniotic fluid could be used as additional parameters for prenatal screening of trissomy 21 and that S100B values are associated with the gestational age.     

S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma

Although histochemical staining of the S100 protein family has been used for many years in the diagnosis of malignant melanoma, recent studies suggest one of the proteins comprising the S100 family, S100B, has particular utility in many aspects of the clinical management of malignant melanoma. This protein has been shown to be of use in staging malignant melanoma, in establishing prognosis, in evaluating treatment success and in predicting relapse. S100B is an independent prognostic factor and pretreatment circulating S100B concentrations predict duration of survival in melanoma patients. Survival is significantly longer in melanoma patients with normal S100B levels compared to those with elevated levels. Circulating S100B levels very sensitively detect metastatic growth of malignant melanoma, particularly in stage IV disease where S100B is certainly superior to other laboratory parameters. S100B concentrations reflect tumor mass. Serum S100B levels predict efficacy of treatment. Decreasing S100B concentrations reflect response to therapy while increasing S100B concentrations indicate tumor progression. Circulating S100B has a role to play in the decision to switch treatment regimens.     

ELISA法测定血清S100B蛋白

目的建立ELISA测定血清S100B蛋白的方法。方法制备S100B单克隆和多克隆抗体,以双抗体夹心法测定血清S100B蛋白。结果方法的平均回收率为93.7%-104%,批内及批间平均变异分别为3.7%和5.9%,方法的线性为0-12.5μg/l,参考值范围为0.14-0.38μg/l。结论该法简便、快速、特异、敏感,适于临床常规应用。     

S100B在大鼠心力衰竭模型中的表达

目的 研究钙离子结合蛋白S100B在心力衰竭大鼠心肌细胞中的表达变化.方法 清洁级雄性Sprague-Dawley大鼠,体重(220-240)g,由浙江大学医学院实验动物中心提供.通过缩窄腹主动脉建立心力衰竭大鼠模型,术后第二周仍存活的20只大鼠随机分为手术组(10只)和卡维地洛组(10只),在术后第2周各以生理盐水和卡维地洛灌胃,共4周.假手术组(10只)仅分离腹主动脉不束扎.术后第6周,应用MEDLAB-U/4CS生物信号采集系统测定血流动力学.麻醉处死后,取左室心肌检测S100B蛋白表达,RT-PCR法测定S100BmRNA水平.计基资料以均数±标准差(-x±s)表示,多组间比较应用单因素方差分析法进行分析,两两问比较应用Student-Newman-Keulsa法进行检验.P＜0.05认为差异具有统计学意义.结果 与假手术组比,手术组左心室舒张末压(LVEDP)升高[(24.8±5.2)mmHg vs.(2.1±0.7)mmHg],左心室内压最大收缩和舒张速率(±dp/dtmax)下降[(1543.6±277.9)mmng/s vs.(2640.4±481.3)mmHg/s和(-1352.5±202.3)mmHg/s vs.(-1873.2±412.3)mmHg/s],差异有统计学意义(P＜0.01,P＜0.01和P＜0.05).卡维地洛组的LVEDP(12.7±1.1)mmHg,介于手术组和假手术组之间,差异有统计学意义(P＜0.01);±dp/dtmax为(2372.3±92.6)mmHg/s和(-1786.4±62.6)mmHg/s,明显高于手术组,差异有统计学意义(P＜0.01).假手术组心肌没有S100B阳性细胞和S100BmRNA表达;手术组心肌有大量胞浆棕黄色的S100B阳性细胞和S100BmRNA表达;卡维地洛组S100B阳性细胞数明显减少而且S100BmRNA水平低,差异有统计学意义(P＜0.01).S100BmRNA表达量与LVEDP、+dp/dtmax、-dp/dtmax相关,相关系数r=0.847、-0.853、-0.689,P均＜0.01.结论 S100B在衰竭心肌细胞中表达明显增多,与心功能呈负相关;在心力衰竭中起负调控作用.     

血清S100B检测对创伤性脑损伤的诊断价值

目的 探讨血清S100钙结合蛋白B(S100B)在判断创伤性脑损伤(TBI)患者病情严重程度和预后评估中的应用价值.方法 选取该院救治的106例TBI患者,分别于伤后第1、3、5天检测血清S100B的水平;根据入院时的格拉斯哥昏迷评分(GCS)分为3组:轻度组65例、中度组14例、重度组27例;按照3个月时回访的格拉斯...     

纳洛酮对脑出血大鼠抓握能力的改善及血清S100B水平的影响

目的：探讨纳洛酮对脑出血大鼠抓握能力的改善及血清S100B水平的影响，为其临床应用提供理论依据。方法：40只SD大鼠随机分成假手术组，手术组，纳洛酮组，脑复康组，参照Rosenberg法制作大鼠脑出血模型，造模第二天测定大鼠抓握能力，用ELISA法检测造模后24小时及48小时血清S100B水平。结果：（1）纳洛酮组大鼠抓握能力明显好于手术组，两者比较有显著差异（P<0.05）。（2）纳洛酮组大鼠血清S100B水平明显低于手术组, 两者比较有显著差异（P<0.05）。结论：纳洛酮能明显改善脑出血大鼠抓握能力，降低血清S100B水平，具有神经保护作用。     

血清S100B检测在急性颅脑损伤预后评估中的临床价值

目的探讨血清S100B在急性颅脑损伤预后评估的临床应用价值.方法以电化学发光免疫法检测77例急性颅脑损伤患者伤后3 h内的血清S100B含量,以扩展Glasgow结果评分评价其伤后6个月的康复情况,并对两者的关系进行受试者操作特性分析.结果血清S100B含量低于0.42 μg/L者预后良好,其敏感度为78.8%,特异度为88.9%.结论血清S100B可以用作评估急性颅脑损伤预后的神经化学标志物.     

脑脊液S100钙结合蛋白B在创伤性颅脑损伤中应用研究

目的 探讨脑脊液S100钙结合蛋白B(S100B)在评估创伤性颅脑损伤(TBI)严重程度和预后中的价值.方法 选取自2017年10月至2019年6月苏州大学附属常熟医院收治的43例TBI患者为研究对象,根据格拉斯哥结局量表分为预后良好组(n=20)与预后不良组(n=23).通过脑室外引流获取脑脊液,测定患者术后6、12...     

S100B and the influence of seasonal variation

Background A blood test for S100B can be used to rule out intracranial complications after minor head injury and thereby reduce the need for computed tomography (CT) examinations. The aim of this study was to investigate the clinical importance of a possible influence of seasonal variation on S100B. Methods The individual seasonal variation of S100B in 69 healthy volunteers living at latitudes with extremely variable seasonal exposure to sunlight was investigated. Results The mean serum concentration of S100B was 13% higher in August than in February, but however, not statistically significant (p?=?0.068). A good agreement between summer and winter S100B values was confirmed by Bland-Altman analysis and a significant correlation (r?=?0.317, p?=?0.008) was shown between summer and winter S100B values. Conclusion This study did not show any clinical importance of seasonal variation of S100B that may influence the decision of CT scanning patients with head injuries.     

侧脑室注射S100A4蛋白对局灶性脑梗死大鼠神经功能及脑内S100B表达的影响

目的：观察经侧脑室注射S100A4蛋白对脑梗死大鼠神经功能以及脑内S100B蛋白表达的影响。方法：36只健康成年SD大鼠线栓法成功复制大鼠大脑中动脉闭塞模型（MCA0）,随机分为A、B组各18只,术后第1天A组侧脑室行人工脑脊液注射;B组行S100A4蛋白注射。在MACO术后第1、7及14d时各组各取6只行神经行为学评分,免疫组织化学法检测脑内S100B蛋白的表达情况。结果：B组大鼠在术后第7,14天时神经行为学评分与术后第1天比较有明显下降（1．96±0．49、1．75±0．40与2．94±0．72,P〈0．05）,并低于相同时间点A组大鼠。S100B阳性细胞数在术后第7天2组脑内达到峰值,以后开始减少,2组间比较,B组少于A组（P〈0．05）。结论：侧脑室注射S100A4蛋白可一定程度改善脑梗死大鼠神经行为学功能缺损,减少S100B蛋白在脑内的表达。     

血清S100蛋白水平与大肠癌之间的相关性研究

目的探讨血清S100蛋白水平与大肠癌的发生、分期及病理类型之间的相关性。方法收集东西湖区人民医院普外科及肿瘤科大肠癌患者111例,其中低分化腺癌27例,中分化腺癌35例,高分化腺癌49例;按照Dukes分期标准又分为Ⅰ期31例,Ⅱ期29例,Ⅲ期34例,Ⅳ期17例。所有病例的诊断均经病理切片和组化染色确诊。健康对照组为本院健康体检人群104例。两组年龄和性别比例匹配。所有研究对象均测定血清S100蛋白水平。检测方法为化学发光分析法。结果与健康对照组比较,大肠癌组血清S100蛋白水平明显升高,差异有统计学意义(P<0.05);不同Dukes分期间血清S100蛋白水平比较,差异均有统计学意义(P<0.05);不同病理类型之间比较,血清S100蛋白水平差异无统计学意义(P>0.05)。结论血清S100蛋白水平可能与大肠癌的发生和分期相关,但与病理类型无关。     

Serum S100B protein is associated with depressive symptoms in patients with end-stage renal disease

Objectives

Depression is associated with a poorer prognosis in patients with end-stage renal disease (ESRD). Increasing evidence indicates that glial pathology and blood–brain-barrier (BBB) dysfunction are involved in the pathophysiology of depression. S100B, a protein expressed in astro- and oligodendroglia in the human brain is considered a biomarker of depression. Our objective was to investigate the relationship between S100B and depressive symptoms in patients undergoing hemodialysis (HD).

Design and methods

Seventy-eight Korean patients undergoing chronic HD without significant neurological issues participated in a cross-sectional observation study. Depressive symptoms were assessed with the Beck Depression Inventory-II (BDI-II), and serum S100B levels were measured using blood samples obtained prior to a mid-week HD session.

Results

The mean age of patients was 59.0 years, and the mean dialysis duration was 51.7 months. About 45% of patients undergoing HD met criteria for depression (BDI-II ≥ 20). Serum S100B levels were significantly higher in patients with depression compared with patients without depression (115.1 ± 45.4 vs. 66.1 ± 35.3 pg/mL, p < 0.001). S100B (r = 0.556, p < 0.001) and high-sensitivity C-reactive protein (hs-CRP; r = 0.422, p < 0.001) and β2-microglobulin (r = 0.391, p < 0.001) levels were positively correlated with BDI-II scores. A multivariate regression analysis showed that both S100B and hs-CRP were significantly associated with BDI-II scores.

Conclusions

The results showed a close association between S100B and depressive symptoms in patients undergoing HD. However, the mechanisms underlying this relationship are currently unknown and warrant further investigation.     

卒中散对脑出血大鼠抓握能力的改善及血清S100B水平的影响

目的:探讨卒中散对脑出血大鼠抓握能力的改善及血清S100B水平的影响,为其临床应用提供理论依据。方法:40只SD大鼠随机分成假手术组、手术组、卒中散组、脑复康组,参照Rosenberg法制作大鼠脑出血模型,造模第2天测定大鼠抓握能力,用ELISA法检测造模后24h及48h血清S100B水平。结果:(1)卒中散组大鼠抓握能力明显好于手术组,两者比较有显著差异(P<0.05)。(2)卒中散组大鼠血清S100B水平明显低于手术组,两者比较有显著差异(P<0.05)。结论:卒中散能明显改善脑出血大鼠抓握能力,降低血清S100B水平,具有神经保护作用。     

监测窒息新生儿血清BDNF、S100B及aEEG动态变化及对脑损伤预测价值

目的探讨监测窒息新生儿血清脑源性神经营养因子（BDNF）、S100B蛋白及振幅整合脑电图（aEEG）动态变化,分析其对脑损伤的预测价值。 方法选择2019年6月至2021年3月上海交通大学附属苏州九龙医院收治的103例窒息新生儿（窒息组）和39例健康足月新生儿（对照组）,其中窒息组新生儿又被分为轻度窒息组（1/5 min Apgar评分＜7分,脐动脉血气分析pH＜7.2,65例）和重度窒息组（1/5 min Apgar评分＜5分,脐动脉血气分析pH＜7.0,38例）。于受试儿出生后6 h、24 h、3 d检测血清BDNF、S100B水平,行aEEG检查分析脑电波背景活动,窒息新生儿出生后第7天行颅脑MRI检查。二元Logistic回归分析BDNF、S100B、脑电波背景活动与窒息新生儿脑损伤的关系。受试者工作特征曲线（ROC）分析BDNF、S100B、脑电波背景活动鉴别窒息新生儿脑损伤的价值。 结果轻度窒息组和重度窒息组患儿出生后6 h、24 h、3 d血清BDNF、S100B水平呈先增高后下降的趋势（P＜0.05）,重度窒息组出生后6 h、24 h、3 d血清BDNF、S100B水平高于轻度窒息组和对照组（P＜0.05）。出生后6 h、24 h、3 d脑电波背景活动与窒息程度呈正相关（r_s=0.776、0.895、0.735,P均＜0.05）。本组103例窒息新生儿发生脑损伤41例,出生后24 h的高BDNF、高S100B、脑电波背景活动重度异常与窒息新生儿脑损伤的发生有关（P＜0.05）。联合出生后24 h的BDNF、S100B、脑电波背景活动诊断窒息新生儿脑损伤的曲线下面积为0.911,高于单独诊断的0.696、0.697、0.707（P＜0.05）。 结论出生后24 h血清BDNF、S100B水平升高,aEEG脑电波背景活动严重异常与窒息新生儿脑损伤的发生有关,监测血清BDNF、S100B及aEEG有助于评估窒息新生儿脑损伤风险。     

Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure

Objective

To investigate the correlations between S100B and the severity of cardiac dysfunction, renal insufficiency (RI) and prognosis in chronic heart failure (CHF).

Method

Serum levels of S100B, TNF-α, high sensitivity CRP and NT-proBNP were determined in CHF patients with (n = 96) and without RI (n = 146). Patients with RI only (n = 62) and control subjects (n = 64) served for comparison. Patients were followed up for one year.

Results

S100B levels were higher in CHF patients with a further elevation in those with RI (P < 0.01). Serum S100B levels correlated with left ventricular ejection fraction, left ventricular end-diastolic volume and NT-proBNP in CHF patients, and eGFR in patients with RI (all P < 0.05). Increased S100B levels were associated with major cardiac events (MCE), and were independently associated with the presence of CHF (all P < 0.05).

Conclusion

Increased serum S100B levels were associated with the severity of cardiac dysfunction, RI and an adverse prognosis in CHF patients. It represents an independent risk factor for CHF.     

Influence of anticoagulants on the measurement of S100B protein in blood

OBJECTIVE: Evaluate anticoagulants influence on blood S100B levels. DESIGN AND METHODS: Blood from 18 healthy adult subjects were collected using: no anticoagulants; EDTA; heparin; and citrate. S100B levels were determined using LIA-mat assay. RESULTS: Heparin and citrate increased S100B levels (p<0.001), whereas EDTA had no effect (p=0.24). Heparin samples were highly (r2=0.97, p<0.001), citrate samples were moderately (r2=0.49, p<0.001), and EDTA samples were not (r2=0.22, p=0.059) correlated with serum samples. CONCLUSION: When anticoagulant is required, heparin should be the primary choice.     

Influence of anticoagulants on the measurement of S100B protein in blood

OBJECTIVE: Evaluate anticoagulants influence on plasma S100B levels. DESIGN AND METHODS: Blood were collected from 18 healthy adult subjects using: no anticoagulants, EDTA, heparin, and citrate. S100B levels were determined using LIA-mat assay. RESULTS: Heparin plasma and citrate increased plasma S100B levels (p < 0.001), whereas EDTA had no effect (p = 0.24). Heparin plasma samples were highly (r2 = 0.97, p < 0.001), citrate samples were moderately (r2 = 0.49, p < 0.001), and EDTA samples were not (r2 = 0.22, p = 0.059) correlated with serum samples. CONCLUSIONS: When anticoagulant is required, heparin plasma should be the primary choice for measurement of S100 B levels.